Key result
Tenecteplase offers improved pharmacokinetic properties over alteplase for acute ischemic stroke, including a longer half-life that enables single-bolus administration.
Why the study?
Alteplase is most frequently used for thrombolysis in acute ischemic stroke, but tenecteplase has improved pharmacokinetic properties and may offer a significant advantage with similar or higher efficacy and safety.
Does tenecteplase offer improved pharmacokinetic properties and clinical advantages compared to alteplase in patients with acute ischemic stroke?
Does tenecteplase offer improved pharmacokinetic properties and clinical advantages compared to alteplase in patients with acute ischemic stroke?
Tenecteplase's longer half-life allows for single-bolus administration, offering a significant pharmacokinetic advantage over alteplase for acute ischemic stroke thrombolysis.
PK advantages may support tenecteplase in AIS; leaves open definitive replacement of alteplase pending larger trials.
INTRODUCTION: The drug most frequently used for thrombolysis in cases of acute ischemic stroke (AIS) is alteplase. However, there is moderate-to-high-quality evidence that tenecteplase has similar or higher efficacy and safety. With improved pharmacokinetic properties over alteplase, tenecteplase could be a significant advantage in treating AIS. AREAS COVERED: After conducting an extensive search on Scopus and PubMed, this manuscript reviews and compares the pharmacokinetic properties of alteplase and tenecteplase. Additionally, it provides information on pharmacodynamics, clinical efficacy, safety, tolerability, and drug-drug interactions. EXPERT OPINION: The pharmacokinetic profile of alteplase and tenecteplase is derived from studies in patients with acute myocardial infarction. Thanks to its pharmacokinetic properties, tenecteplase is the drug closest to being the ideal fibrinolytic for AIS. Its longer half-life enables a single-bolus administration, which is particularly useful in emergencies. Tenecteplase has proven to have a good efficacy and safety profile in randomized clinical trials. Although we are awaiting the results of the ongoing phase 3 randomized clinical trials, we believe that tenecteplase has the potential to revolutionize the treatment of AIS through thrombolysis.
No takes yet. Share an insight, caveat, or question.
Marè et al. (2024) conducted a review in Acute ischemic stroke (AIS). Tenecteplase vs. Alteplase was evaluated. Tenecteplase offers improved pharmacokinetic properties over alteplase for acute ischemic stroke, including a longer half-life that enables single-bolus administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: